Tolerability profile of the current antifungal armoury-Reference-Cited by-同舟云学术

Tolerability profile of the current antifungal armoury

Published:2018-01-01 Issue:suppl_1 Volume:73 Page:i26-i32
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Mourad Ahmad¹,Perfect John R¹

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA

Abstract

AbstractThe tolerability of available antifungal agents is essential to the final outcome of the management of invasive mycoses. There are limited classes of antifungal agents for use, and they can have serious direct toxicities and/or drug–drug interactions. In this review, we examine the common toxicities noted for antifungal agents and attempt to both identify the issues around the adverse events and provide clinical context for their occurrence in these fragile patients.

Funder

NIH

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/73/suppl_1/i26/28942664/dkx446.pdf

Reference79 articles.

1. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study;Garey;Clin Infect Dis,2006

2. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality;Morrell;Antimicrob Agents Chemother,2005

3. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis;Chamilos;Clin Infect Dis,2008